Cargando…

γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells

INTRODUCTION: Inappropriate Notch signaling, downstream of γ-secretase activity, is understood to have tumor-promoting function and to be associated with poor outcome in cancer, of the breast in particular. The molecular basis of antitumoral effects of its inhibitors, however, remains poorly charact...

Descripción completa

Detalles Bibliográficos
Autores principales:	Séveno, Céline, Loussouarn, Delphine, Bréchet, Sophie, Campone, Mario, Juin, Philippe, Barillé-Nion, Sophie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446359/ https://www.ncbi.nlm.nih.gov/pubmed/22703841 http://dx.doi.org/10.1186/bcr3214

Ejemplares similares

Bim, Puma and Noxa upregulation by Naftopidil sensitizes ovarian cancer to the BH3-mimetic ABT-737 and the MEK inhibitor Trametinib
por: Florent, Romane, et al.
Publicado: (2020)

YM155 potently triggers cell death in breast cancer cells through an autophagy-NF-kB network
por: Véquaud, Eloïse, et al.
Publicado: (2015)

The BH3 mimetic ABT-737 increases treatment efficiency of paclitaxel against hepatoblastoma
por: Lieber, Justus, et al.
Publicado: (2011)

The BH3-mimetic ABT-737 effectively kills acute myeloid leukemia initiating cells
por: Baev, Denis V., et al.
Publicado: (2014)

Understanding sensitivity to BH3 mimetics: ABT-737 as a case study to foresee the complexities of personalized medicine
por: Stamelos, Vasileios A, et al.
Publicado: (2012)

The BH3 mimetic drug ABT-737 induces apoptosis and acts synergistically with chemotherapeutic drugs in thyroid carcinoma cells
por: Broecker-Preuss, Martina, et al.
Publicado: (2016)

The ratio of Mcl-1 and Noxa determines ABT737 resistance in squamous cell carcinoma of the skin
por: Geserick, P, et al.
Publicado: (2014)

The ratio of Mcl-1 and Noxa determines ABT737 resistance in squamous cell carcinoma of the skin
por: Geserick, P, et al.
Publicado: (2015)

Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner()()
por: Kiprianova, Irina, et al.
Publicado: (2015)

Upregulating Noxa by ER Stress, Celastrol Exerts Synergistic Anti-Cancer Activity in Combination with ABT-737 in Human Hepatocellular Carcinoma Cells
por: Zhu, Hong, et al.
Publicado: (2012)

Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer
por: Shin, Ji-Ae, et al.
Publicado: (2015)

The Combination of BH3-Mimetic ABT-737 with the Alkylating Agent Temozolomide Induces Strong Synergistic Killing of Melanoma Cells Independent of p53
por: Reuland, Steven N., et al.
Publicado: (2011)

Metastatic SW620 colon cancer cells are primed for death when detached and can be sensitized to anoikis by the BH3-mimetic ABT-737
por: Maamer-Azzabi, A, et al.
Publicado: (2013)

Noxa determines localization and stability of MCL-1 and consequently ABT-737 sensitivity in small cell lung cancer
por: Nakajima, W, et al.
Publicado: (2014)

ABT-737, a BH3 Mimetic, Enhances the Therapeutic Effects of Ionizing Radiation in K-ras Mutant Non-Small Cell Lung Cancer Preclinical Model
por: Lee, Jung Mo, et al.
Publicado: (2022)

By reducing global mRNA translation in several ways, 2-deoxyglucose lowers MCL-1 protein and sensitizes hemopoietic tumor cells to BH3 mimetic ABT737
por: Tailler, Maximilien, et al.
Publicado: (2018)

ABT-737 synergizes with Bortezomib to kill melanoma cells
por: Reuland, Steven N., et al.
Publicado: (2011)

An Anti-PSMA Immunotoxin Reduces Mcl-1 and Bcl2A1 and Specifically Induces in Combination with the BAD-Like BH3 Mimetic ABT-737 Apoptosis in Prostate Cancer Cells
por: Masilamani, Anie P., et al.
Publicado: (2020)

Chemotherapeutic drugs sensitize human renal cell carcinoma cells to ABT-737 by a mechanism involving the Noxa-dependent inactivation of Mcl-1 or A1
por: Zall, Henry, et al.
Publicado: (2010)

Use of Human Cancer Cell Lines Mitochondria to Explore the Mechanisms of BH3 Peptides and ABT-737-Induced Mitochondrial Membrane Permeabilization
por: Buron, Nelly, et al.
Publicado: (2010)

Synergistic cytotoxicity of perifosine and ABT‐737 to colon cancer cells
por: Adamová, Barbora, et al.
Publicado: (2022)

Preferential targeting of cancer stem cells in the radiosensitizing effect of ABT-737 on HNSCC
por: Gilormini, Marion, et al.
Publicado: (2016)

Comparison of in vitro antileukemic activity of obatoclax and ABT-737
por: Opydo-Chanek, Małgorzata, et al.
Publicado: (2016)

Targeting of BCL-2 Family Members during Anticancer Treatment: A Necessary Compromise between Individual Cell and Ecosystemic Responses?
por: Barillé-Nion, Sophie, et al.
Publicado: (2020)

Interactions between cancer-associated fibroblasts and tumor cells promote MCL-1 dependency in estrogen receptor-positive breast cancers
por: Louault, K., et al.
Publicado: (2019)

Human Pluripotent Stem Cells and Derived Neuroprogenitors Display Differential Degrees of Susceptibility to BH3 Mimetics ABT-263, WEHI-539 and ABT-199
por: García, Carolina Paola, et al.
Publicado: (2016)

AT101 [(-)-Gossypol] Selectively Inhibits MCL1 and Sensitizes Carcinoma to BH3 Mimetics by Inducing and Stabilizing NOXA
por: Mallick, David J., et al.
Publicado: (2020)

BH3 mimetic ABT-263 enhances the anticancer effects of apigenin in tumor cells with activating EGFR mutation
por: Zhan, Yihong, et al.
Publicado: (2019)

Data on the DNA damaging and mutagenic potential of the BH3-mimetics ABT-263/Navitoclax and TW-37
por: Green, Maja M., et al.
Publicado: (2016)

ABT-737 and/or folate reverse the PDGF-induced alterations in the mitochondrial apoptotic pathway in low-grade glioma patients
por: Debien, Emilie, et al.
Publicado: (2011)

Inhibition of MARCH5 ubiquitin ligase abrogates MCL1-dependent resistance to BH3 mimetics via NOXA
por: Subramanian, Aishwarya, et al.
Publicado: (2016)

Notch2 Signaling Sensitizes Endothelial Cells to Apoptosis by Negatively Regulating the Key Protective Molecule Survivin
por: Quillard, Thibaut, et al.
Publicado: (2009)

Efficient Elimination of Cancer Cells by Deoxyglucose-ABT-263/737 Combination Therapy
por: Yamaguchi, Ryuji, et al.
Publicado: (2011)

Melatonin Can Modulate the Effect of Navitoclax (ABT-737) in HL-60 Cells
por: Lomovsky, Alexey, et al.
Publicado: (2020)

Survivin contributes to DNA repair by homologous recombination in breast cancer cells
por: Véquaud, Eloïse, et al.
Publicado: (2015)

Exploiting the Synergy between Carboplatin and ABT-737 in the Treatment of Ovarian Carcinomas
por: Jain, Harsh Vardhan, et al.
Publicado: (2014)

Combination treatment with ABT-737 and chloroquine in preclinical models of small cell lung cancer
por: Zinn, Rebekah L, et al.
Publicado: (2013)

ABT-737 ameliorates docetaxel resistance in triple negative breast cancer cell line
por: Hwang, Eunjoo, et al.
Publicado: (2018)

Noxa and Mcl-1 expression influence the sensitivity to BH3-mimetics that target Bcl-xL in patient-derived glioma stem cells
por: Vera, Mariana Belén, et al.
Publicado: (2022)

Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B
por: Rooswinkel, R W, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_vk08mmb5rkkeuk4e4ctbecmg7l